Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Clinical trial NCT03725059 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03725059
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-27
- Primary completion
- 2031-01-24
- Enrollment
- 1240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.